Impact of farnesylation inhibitors on survival in Hutchinson-Gilford progeria syndrome.
Level 3 - non-randomized controlled study
Non-randomized matched cohort study comparing treated trial participants to untreated natural history controls
PubMed 24795390 · doi:10.1161/CIRCULATIONAHA.113.008285
What was done
Kaplan-Meier survival analysis comparing patients with Hutchinson-Gilford progeria syndrome treated with protein farnesylation inhibitors in single-arm clinical trials against an age- and sex-matched untreated natural history cohort, with a median follow-up of 5.3 years from treatment initiation.
What was found
Untreated natural history mean survival was 14.6 years. In the matched analysis of 43 treated versus 43 untreated subjects, 5 treated patients died compared to 21 untreated patients. Farnesylation inhibitor treatment was associated with reduced mortality (hazard ratio 0.13, 95% CI 0.04-0.37, P < 0.001) and an estimated 1.6-year increase in mean survival.
Why it matters
This study establishes a natural history survival benchmark and provides the first comparative evidence that disease-targeted farnesylation inhibitors improve survival in Hutchinson-Gilford progeria syndrome.
Limits
The study is non-randomized and uses an external matched control group, introducing potential confounding and selection bias. The sample size is small (86 matched subjects), reflecting an ultrarare disease. Specific drug regimens, dosages, and adverse events were not detailed in the abstract.
Cited by
- supports Children born with progeria typically do not live past their teens and suffer from accelerated aging, cardiomyopathy, and stroke.